The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | State-of-the-art first-line therapy for mCRC
Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, explores the first-line treatment of patients with metastatic colorectal cancer (mCRC), including molecular drivers of disease such as microsatellite instability, as well as EGFR/BRAF/RAS mutations which can be targeted by immunotherapies or targeted therapies respectively. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3ZWhLDH
